Indapta Therapeutics

Focus: Indapta Therapeutics is a public-stage biotech company focused on developing allogeneic FcγR-deficient natural killer cell therapies for oncology and neurology indications. The company operates as a lean, early-stage player in the cell therapy space.

Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Indapta Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Indapta Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

IDP-023

Multiple Sclerosis

Phase 1

Clinical Trials (1)

NCT06677710IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Phase 1

Help build intelligence for Indapta Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering NK cell engineering platform with proprietary FcγR-deficient approach, offering exposure to cutting-edge cell therapy science
Public company status provides potential equity upside and access to capital markets without the funding uncertainty of private biotechs
Operating in high-validation therapeutic areas (NHL, Multiple Sclerosis) with significant unmet medical need

Watch Out For

Zero active job openings and minimal public hiring activity suggest a very lean organization with limited career mobility or mentorship infrastructure
No approved products, revenue, or phase 3 data creates execution risk; both programs are early-stage (Phase 1/2 or Phase 1)

Generated by Claude from Indapta Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

IDP-023

NHL

Phase 1/2

Clinical Trials (1)

NCT06119685IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Phase 1/2